A study of advanced melanoma patients found that those with sufficient vitamin D levels had significantly better responses to anti-PD-1 immunotherapy, including higher tumor response rates and longer survival without disease progression.
Patients with adequate vitamin D had a median progression-free survival of 11.25 months, more than double the 5.75 months seen in vitamin D-deficient patients and showed a trend toward longer overall survival.
It helps optimize the immune environment for cancer treatment, potentially by enhancing the activity of cancer-killing T-cells and controlling inflammation that can hinder an effective immune response.
While the body’s natural production of vitamin D via sunlight is efficient, the research emphasizes achieving nutrient sufficiency—often through medical supplementation for patients—rather than advocating for unfettered sun exposure, which carries its own risks.
Monitoring and maintaining optimal vitamin D levels (typically 30-50 ng/mL) through blood tests and supervised supplementation should become a standard, low-cost adjunctive strategy for melanoma patients undergoing immunotherapy.
In a finding that bridges ancient wisdom with cutting-edge oncology, new research reveals that a simple, centuries-revered nutrient—vitamin D—can significantly improve the effectiveness of modern cancer immunotherapy. A study published in the journal Cancer has demonstrated that patients with advanced skin cancer who maintain sufficient vitamin D levels experience markedly better treatment outcomes, including longer periods without disease progression and extended overall survival. This discovery, emerging from the analysis of 200 melanoma patients, challenges simplistic public health narratives around sun exposure and positions vitamin D optimization as a critical, low-cost ally in the fight against one of medicine’s most formidable foes.
Read Full Article: https://www.naturalnews.com/2026-03-26-study-vitamin-d-boosts-skin-cancer-treatment.html
